X
53.41
-1.32 (-2.41%)
| Previous Close | 54.73 |
| Open | 54.43 |
| Volume | 1,263,915 |
| Avg. Volume (3M) | 1,470,539 |
| Market Cap | 5,162,907,136 |
| Price / Sales | 591.55 |
| Price / Book | 3.95 |
| 52 Weeks Range |
| Operating Margin (TTM) | -969.84% |
| Diluted EPS (TTM) | -3.22 |
| Total Debt/Equity (MRQ) | 1.23% |
| Current Ratio (MRQ) | 17.66 |
| Operating Cash Flow (TTM) | -196.85 M |
| Levered Free Cash Flow (TTM) | -128.49 M |
| Return on Assets (TTM) | -22.03% |
| Return on Equity (TTM) | -31.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Xenon Pharmaceuticals Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.14% |
| % Held by Institutions | 103.51% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 97.00 (Baird, 81.61%) | Buy |
| Median | 77.00 (44.17%) | |
| Low | 64.00 (Wedbush, 19.83%) | Buy |
| Average | 78.83 (47.59%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 61.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Deutsche Bank | 10 Mar 2026 | 90.00 (68.51%) | Buy | 60.61 |
| HC Wainwright & Co. | 10 Mar 2026 | 74.00 (38.55%) | Buy | 60.61 |
| Wedbush | 10 Mar 2026 | 64.00 (19.83%) | Buy | 60.61 |
| Wells Fargo | 10 Mar 2026 | 68.00 (27.32%) | Buy | 60.61 |
| Baird | 09 Mar 2026 | 97.00 (81.61%) | Buy | 62.76 |
| Needham | 09 Mar 2026 | 80.00 (49.78%) | Buy | 62.76 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |